Time filter

Source Type

News Article | May 10, 2017
Site: www.businesswire.com

KITCHENER, Ontario--(BUSINESS WIRE)--Miovision, a global leader in smart traffic technology, is building the foundation for smart cities with the world’s most advanced traffic AI. Earlier this year, Miovision launched Miovision Labs to be the research and testing ground for the next generation of traffic technology. Part of that work is helping cities use traffic data to make better decisions, and study how emerging technologies such as computer vision, deep learning, big data analytics and embedded device design can play roles. Miovision Labs explores new ways to make intersections more responsive to real-time traffic conditions. They do this using industry-leading NVIDIA graphics processing units (GPUs) to quickly analyze huge volumes of data, and in doing so, bring their AI capabilities to a whole new level. “Miovision is creating the world’s first neural network for traffic,” said Kurtis McBride, Miovision CEO and co-founder. “In the near future, the combination of our technology will make it easier for cities to monitor traffic and address problems to help people get around more quickly and safely.” Today, Miovision transforms video of vehicle, cyclist and pedestrian traffic into analytics via the cloud where it is processed by the NVIDIA GPUs and converted to usable data to help city planners improve traffic flow. Eventually, AI will be built into devices to process data at the roadside. That information will then be fed back into the system to alert the right departments in real time. For example, a sensor might detect a double-parked car blocking a lane of traffic and alert traffic managers to adjust nearby traffic lights to improve vehicle flow. They could also alert police in case of an emergency. The goal is to use Miovision’s advanced AI in real time so that traffic incidents can be addressed immediately. Responsive cities are smarter cities, and giving them the ability to react quickly helps cities get on the right track to achieving their smart city visions. “Today, we’re helping cities with information and technology to build better transportation systems, but we’ve only scratched the surface,” McBride said. “Through the research we’re doing at Miovision Labs, using NVIDIA GPUs, with academic partners like the University of Waterloo, University of Toronto, and University of Sherbrooke, we’re building a neural network for transportation that will be the foundation for smart cities of tomorrow.” McBride will speak about Miovision’s deep learning traffic analytics system today at the GPU Technology Conference in Silicon Valley. Miovision’s mission is to provide the foundation for tomorrow’s smart cities by reinventing the way traffic networks are managed today. Backed by the world’s most advanced traffic AI, Miovision’s innovations in traffic signal planning and operations have made it possible for cities to improve the transportation experience for drivers, cyclists and pedestrians for the past 11 years. With offices in Kitchener, Canada and Cologne, Germany, Miovision serves over 17,000 municipalities worldwide. For more information, visit www.miovision.com.


TORONTO, ON / ACCESSWIRE / November 17, 2016 / BFK Capital Corp. (TSXV: BFK.P) ("BFK"), a Capital Pool Company, and The Hydropothecary Corporation ("THC") are pleased to announce that they have entered into a non-binding letter of intent to complete a business combination (the "Transaction"). The letter of intent was negotiated at arm's length and is effective as of November 16, 2016. BFK is a company existing under the laws of Ontario, a reporting issuer in British Columbia, Alberta and Ontario, and a Capital Pool Company listed on the TSX Venture Exchange (the "Exchange"). BFK has not commenced commercial operations and has no assets other than cash. If completed, the Transaction will constitute BFK's Qualifying Transaction pursuant to the policies of the Exchange. BFK currently has 2,756,665 common shares ("BFK Shares") issued and outstanding, of which 1,676,665 BFK Shares are currently held in escrow pursuant to the policies of the Exchange. In addition, BFK has outstanding stock options to purchase up to an aggregate of 266,665 BFK Shares at a price of $0.60 per share (the "BFK Options") to directors and officers. Other than these BFK Shares and BFK Options, no other securities of BFK are outstanding. Further information concerning BFK can be found in the prospectus of BFK dated October 23, 2014, which is available under BFK's profile on SEDAR at www.sedar.com. THC, through its wholly-owned subsidiary, 167151 Canada Inc. ("167151"), is licensed under the Access to Cannabis for Medical Purposes Regulations to cultivate and sell marijuana seeds and plants and dried marijuana product and to produce marijuana oils, marijuana resins and fresh marijuana products. THC's facilities are located in Gatineau, Québec. THC is a private company existing under the laws of Canada which was incorporated on August 13, 2013. THC currently has 7,346,637 common shares ("THC Shares") issued and outstanding. In addition, THC has issued and outstanding: (i) stock options to purchase up to an aggregate of 835,649 THC Shares at exercise prices ranging between $1.00 and $4.50 per share (the "THC Options"); (ii) common share purchase warrants to purchase up to an aggregate of 1,850,905 THC Shares at exercise prices ranging between $4.00 and $6.23 per share (based on current exchange rates for certain warrants exercisable at US$4.60 per share) (the "THC Warrants"); (iii) $345,000 principal amount of unsecured convertible debentures (the "THC Unsecured Debentures"), the principal amount of which is convertible into units of THC at a price of $4.50 per unit, each unit consisting of one THC Share and one common share purchase warrant exercisable to acquire one THC Share at an exercise price of $5.00 per share for a period of two years from the date of issuance; (iv) US$3,275,000 principal amount of secured convertible debentures (the "THC Secured Debentures"), the principal amount of which is convertible into THC Shares at a price of US$4.20 per share. Other than these THC Shares, THC Options, THC Warrants, THC Unsecured Debentures and THC Secured Debentures, no other securities of THC are issued and outstanding. The THC Shares are widely held and the only shareholders of THC who directly or indirectly own more than 5% of the issued and outstanding THC Shares are Sebastien St-Louis (resident in Ottawa, Ontario), Louis Gagnon (resident in Gatineau, Québec), Adam Miron (resident in Ottawa, Ontario), Dr. Michael Munzar (resident in Montreal Quebec) and Casale HC Limited Partnership (a private investment partnership formed under the laws of Québec), who directly or indirectly hold approximately 9.9%, 8.9%, 8.4%, 5.2% and 7.0% of the outstanding THC Shares, respectively. The remaining THC Shares are held by approximately 152 shareholders. BFK and THC have entered into the letter of intent setting out certain terms and conditions pursuant to which the proposed Transaction will be completed. The transaction terms set out in the letter of intent are non-binding, and the Transaction is subject to the parties successfully negotiating and entering into a definitive business combination agreement in respect of the Transaction (the "Definitive Agreement") on or before December 9, 2016 or such other date as BFK and THC may agree. It is anticipated that the completion of the Transaction will involve the following steps: subject to shareholder approval, BFK will consolidate the outstanding BFK Shares on a 1.5 to 1 basis (the "Consolidation"), so that following the Consolidation, BFK will have 1,837,777 BFK Shares issued and outstanding, as well as the BFK Options which will then be exercisable to acquire 177,777 BFK Shares at a price of $0.90 per share; BFK will then issue BFK Shares to the holders of the THC Shares in exchange for the THC Shares on the basis of six (6) post-Consolidation BFK Shares for each THC Share held (the "Exchange Ratio"), resulting in the issuance of 44,079,822 post-Consolidation BFK Shares to THC's current shareholders; the holders of the THC Options will receive replacement stock options of BFK in exchange for the THC Options on the basis of the Exchange Ratio, resulting in the issuance of BFK stock options exercisable to acquire 5,013,894 post-Consolidation BFK Shares at exercise prices ranging between $0.17 and $0.75 per share; the holders of the THC Warrants will receive replacement common share purchase warrants of BFK in exchange for the THC Warrants on the basis of the Exchange Ratio, resulting in the issuance of BFK warrants exercisable to acquire 11,104,830 post-Consolidation BFK Shares at exercise prices ranging between $0.67 and $1.04 per share; the holders of the THC Unsecured Debentures will receive replacement unsecured debentures of BFK, the principal amount of which will be convertible into units of BFK at a price of $0.75 per unit, each unit consisting of one post-Consolidation BFK Share and one common share purchase warrant exercisable to acquire one post-Consolidation BFK Share at an exercise price of $0.83 per share; the holders of the THC Secured Debentures will receive replacement secured debentures of BFK, the principal amount of which will be convertible into post-Consolidation BFK Shares at a price of US$0.77 per share; and BFK will change its name to "The Hydropothecary Corporation" or such other similar name as the parties may agree to. It is expected that the share exchange will be structured as a three-cornered amalgamation in which THC will amalgamate with a newly incorporated, wholly-owned subsidiary of BFK to be formed solely for the purpose of facilitating the Transaction. Following the amalgamation, the amalgamated company will be a wholly-owned subsidiary of BFK (renamed as the parties may agree to) and 167151 will be a wholly-owned subsidiary of the amalgamated company. The final legal structure for the Transaction, however, will be determined after the parties have considered all applicable tax, securities law, and accounting efficiencies. As a result of the amalgamation, the current holders of THC Shares (not including future shareholders as a result of the Financing referred to below) will hold approximately 96% of the post-Consolidation BFK Shares and the current holders of the BFK Shares will hold approximately 4% of the post-Consolidation BFK Shares. The Transaction will not constitute a Non-Arm's Length Transaction (as such term is defined in the policies of the Exchange). No Insider, promoter or Control Person (as such terms are defined in the policies of the Exchange) of BFK has any material interest in THC prior to giving effect to the Transaction, except that Greg Misztela, a director of BFK, holds or has a beneficial interest in, directly or through affiliates or associates, 104,810 THC Shares, representing approximately 1.43% of the issued and outstanding THC Shares. These shares were acquired in private placements completed prior to the date of this release. The BFK securities issuable under the Transaction will be subject to the escrow requirements of the Exchange and hold periods as required by applicable securities laws. The Transaction is not subject to approval by the shareholders of BFK. However, at a meeting of the shareholders of BFK to be called in connection with the Transaction, the shareholders of BFK will be asked to approve the Consolidation and, to the extent necessary, approve the appointment of new directors as detailed below. The Transaction is subject to approval by the shareholders of THC, which will be sought at a meeting of the shareholders of THC to be held as soon as practicable. Prior to completion of the Transaction, THC intends to complete a brokered private placement of up to 2,900,000 THC Shares at a price of $4.50 per share for gross proceeds of up to $13.05 million (the "Financing"). THC has engaged Canaccord Genuity Corp. to act as agent in respect of the Financing. Under the Transaction, the THC shareholders resulting from the Financing will receive post-Consolidation BFK Shares in exchange for their THC Shares on the basis of the Exchange Ratio. It is a condition to closing of the Transaction that THC completes the Financing for gross proceeds of at least $10 million. Management and Board of Directors of Resulting Issuer Upon completion of the Transaction, it is expected that the board of directors and management of the resulting issuer will consist of the persons identified below. Mr. St-Louis has been the President and Chief Executive Officer of THC since August 2013. Mr. St-Louis is also the President and founder of Shield Real Estate Investments Inc., founded in 2012. Prior to that, he served as a Senior Account Manager at the Business Development Bank of Canada from 2008 to 2011 and as Chief Financial officer of Wholesale Autoparts Warehouses from 2011 to 2012. Mr. St-Louis holds an MBA, DESS, finance from the Université du Québec à Montréal and a Bachelor of Arts from the University of Ottawa. Prior to Joining THC as Chief Financial Officer in 2014, Mr. Chaplin served as V.P. Finance and Administration for Solacom Technologies Inc. from 2011 to 2014, Interim Corporate Controller at Arise Technologies Inc. in 2011, V.P Finance and Administration at BTI Systems Inc. from 2008 to 2010 and Corporate Controller at Corel Corporation from 2001 to 2008. He obtained his Chartered Professional Accountant, Chartered Accountant designation while working for Ernst and Young from 1996 to 1999. Mr. Chaplin holds a Bachelor of Commerce from Carleton University. Mr. Miron has been the Chief Operating Officer of THC since August 2013. Mr. Miron is the co-founder of iPolitics.ca and was the CIO from 2010 to 2013 and was the National Director of the Federal Liberal Commission from 2007 to 2009 and was responsible for the Federal Liberal Party's online election campaigns. He has experience with online marketing and sales, and brand development. Mr. Miron has also run political campaigns in Canada and abroad. Dr. Munzar is a clinician and is currently serving as Medical Director of Statcare medical clinic in Pointe Claire, Québec. In addition, Dr. Munzar is on the board of directors of Osta Biotechnologies Inc., and has held the position of Vice President of Medical and Regulatory Affairs at Osta since 2005. He served as Medical Director of Nymox Pharmaceutical Corporation from 1996 to 2004 and as the President of Serex Inc., a wholly owned subsidiary of Nymox, from 2000 to 2004. Dr. Munzar has experience in the regulatory development of drugs and medical devices. He obtained his MDCM from McGill University in 1979. Mr. Ewart has been the Chief Executive Officer of GC-Global Capital Corp. since June 2004, as well as Director and Chief Operating Officer since July 2003. Mr. Ewart was a market analyst with A & E Capital Funding Inc. and Bradstone Equity Partners Inc. between 1998 and 2002 and Vice-President of Quest Investment Corporation between 2002 and 2003. He has experience with bridge financing, financial analysis, quantitative modeling, equities trading and mergers and acquisitions. Mr. Ewart holds an economics degree from McGill University. Mr. Chiara is President and sole owner of Group Mach Inc. He began his career in 1984 as a lawyer specializing in real estate transactions and corporate litigation. In 1999, he ceased practicing law and focused on real estate acquisitions and property development through Mach, a private holding company. Mach and its affiliates hold significant investments representing more than 6.5 million square feet of office buildings located in Montreal and throughout Québec. In addition to office and commercial spaces, Mach owns seven million square feet of industrial space, residential and development properties and land for development. Mr. Chiara holds a commerce degree from McGill University and a law degree from the University of Sherbrooke. Mr. Chiara is an independent trustee of Pro Real Estate Investment Trust. It is expected that the directors of the resulting issuer will include two additional individuals to be determined. During the fiscal year ended July 31, 2016, THC had sales of $1,871,781 and a net loss of $3,354,296. As at July 31, 2016, THC had total assets of $9,510,076 and no long term liabilities. The foregoing financial information is unaudited. Financial information for THC will be provided in the filing statement of BFK to be prepared in connection with the Transaction. The completion of the Transaction is subject to the approval of the Exchange and all other necessary regulatory approvals. It is also subject to additional conditions precedent, including: execution of the Definitive Agreement on or before December 9, 2016 or such other date as BFK and THC may agree; satisfactory completion of due diligence reviews by both parties; approvals of the boards of directors of BFK and THC; completion of the Financing by THC for gross proceeds of at least $10 million; preparation and filing of a filing statement outlining the definitive terms of the Transaction in accordance with the policies of the Exchange; receipt of all director, shareholder and requisite regulatory approvals relating to the Transaction, including, without limitation, the approval of the Exchange; any person who will be a post-closing shareholder of BFK which is required by the Exchange to sign an escrow agreement in accordance with the policies of the Exchange shall have signed and delivered such agreement; each of BFK and THC shall have executed, delivered and performed all covenants on its part to be performed under the Definitive Agreement and all representations and warranties of each party contained in the Definitive Agreement shall be true and correct at the time of closing; and at the time of closing the Transaction, THC's license to produce and sell medical marijuana must be in effect and in good standing. The proposed Transaction is subject to the sponsorship requirements of the Exchange. The parties intend to apply for an exemption from the sponsorship requirements of the Exchange. In the event that an exemption is not available, a sponsor will be identified at a later date and will be announced in a subsequent press release of BFK. An agreement to sponsor should not be construed as an assurance with respect to the merits of the transaction or the likelihood of completion of the proposed Transaction. Further details about the Transaction and the resulting issuer will be provided in the filing statement of BFK to be prepared and filed in respect of the Transaction. Investors are cautioned that, except as disclosed in the filing statement, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a Capital Pool Company should be considered highly speculative. Trading in the BFK Shares will be halted as a result of this announcement. Trading in the BFK Shares will remain halted pending the review of the proposed Transaction by the Exchange. There can be no assurance that trading in the BFK Shares will resume prior to the completion of the Transaction. This press release contains forward-looking information based on current expectations. Statements about the closing of the Transaction, expected terms of the Transaction, the number of securities of BFK that may be issued in connection with the Transaction, the ownership ratio of BFK's shareholders post-closing, and the parties' ability to satisfy closing conditions and receive necessary approvals are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Transaction will occur or that, if the Transaction does occur, it will be completed on the terms described above. BFK and THC assume no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Completion of the transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange Requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative. The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, please contact: TORONTO, ON / ACCESSWIRE / November 17, 2016 / BFK Capital Corp. (TSXV: BFK.P) ("BFK"), a Capital Pool Company, and The Hydropothecary Corporation ("THC") are pleased to announce that they have entered into a non-binding letter of intent to complete a business combination (the "Transaction"). The letter of intent was negotiated at arm's length and is effective as of November 16, 2016. BFK is a company existing under the laws of Ontario, a reporting issuer in British Columbia, Alberta and Ontario, and a Capital Pool Company listed on the TSX Venture Exchange (the "Exchange"). BFK has not commenced commercial operations and has no assets other than cash. If completed, the Transaction will constitute BFK's Qualifying Transaction pursuant to the policies of the Exchange. BFK currently has 2,756,665 common shares ("BFK Shares") issued and outstanding, of which 1,676,665 BFK Shares are currently held in escrow pursuant to the policies of the Exchange. In addition, BFK has outstanding stock options to purchase up to an aggregate of 266,665 BFK Shares at a price of $0.60 per share (the "BFK Options") to directors and officers. Other than these BFK Shares and BFK Options, no other securities of BFK are outstanding. Further information concerning BFK can be found in the prospectus of BFK dated October 23, 2014, which is available under BFK's profile on SEDAR at www.sedar.com. THC, through its wholly-owned subsidiary, 167151 Canada Inc. ("167151"), is licensed under the Access to Cannabis for Medical Purposes Regulations to cultivate and sell marijuana seeds and plants and dried marijuana product and to produce marijuana oils, marijuana resins and fresh marijuana products. THC's facilities are located in Gatineau, Québec. THC is a private company existing under the laws of Canada which was incorporated on August 13, 2013. THC currently has 7,346,637 common shares ("THC Shares") issued and outstanding. In addition, THC has issued and outstanding: (i) stock options to purchase up to an aggregate of 835,649 THC Shares at exercise prices ranging between $1.00 and $4.50 per share (the "THC Options"); (ii) common share purchase warrants to purchase up to an aggregate of 1,850,905 THC Shares at exercise prices ranging between $4.00 and $6.23 per share (based on current exchange rates for certain warrants exercisable at US$4.60 per share) (the "THC Warrants"); (iii) $345,000 principal amount of unsecured convertible debentures (the "THC Unsecured Debentures"), the principal amount of which is convertible into units of THC at a price of $4.50 per unit, each unit consisting of one THC Share and one common share purchase warrant exercisable to acquire one THC Share at an exercise price of $5.00 per share for a period of two years from the date of issuance; (iv) US$3,275,000 principal amount of secured convertible debentures (the "THC Secured Debentures"), the principal amount of which is convertible into THC Shares at a price of US$4.20 per share. Other than these THC Shares, THC Options, THC Warrants, THC Unsecured Debentures and THC Secured Debentures, no other securities of THC are issued and outstanding. The THC Shares are widely held and the only shareholders of THC who directly or indirectly own more than 5% of the issued and outstanding THC Shares are Sebastien St-Louis (resident in Ottawa, Ontario), Louis Gagnon (resident in Gatineau, Québec), Adam Miron (resident in Ottawa, Ontario), Dr. Michael Munzar (resident in Montreal Quebec) and Casale HC Limited Partnership (a private investment partnership formed under the laws of Québec), who directly or indirectly hold approximately 9.9%, 8.9%, 8.4%, 5.2% and 7.0% of the outstanding THC Shares, respectively. The remaining THC Shares are held by approximately 152 shareholders. BFK and THC have entered into the letter of intent setting out certain terms and conditions pursuant to which the proposed Transaction will be completed. The transaction terms set out in the letter of intent are non-binding, and the Transaction is subject to the parties successfully negotiating and entering into a definitive business combination agreement in respect of the Transaction (the "Definitive Agreement") on or before December 9, 2016 or such other date as BFK and THC may agree. It is anticipated that the completion of the Transaction will involve the following steps: subject to shareholder approval, BFK will consolidate the outstanding BFK Shares on a 1.5 to 1 basis (the "Consolidation"), so that following the Consolidation, BFK will have 1,837,777 BFK Shares issued and outstanding, as well as the BFK Options which will then be exercisable to acquire 177,777 BFK Shares at a price of $0.90 per share; BFK will then issue BFK Shares to the holders of the THC Shares in exchange for the THC Shares on the basis of six (6) post-Consolidation BFK Shares for each THC Share held (the "Exchange Ratio"), resulting in the issuance of 44,079,822 post-Consolidation BFK Shares to THC's current shareholders; the holders of the THC Options will receive replacement stock options of BFK in exchange for the THC Options on the basis of the Exchange Ratio, resulting in the issuance of BFK stock options exercisable to acquire 5,013,894 post-Consolidation BFK Shares at exercise prices ranging between $0.17 and $0.75 per share; the holders of the THC Warrants will receive replacement common share purchase warrants of BFK in exchange for the THC Warrants on the basis of the Exchange Ratio, resulting in the issuance of BFK warrants exercisable to acquire 11,104,830 post-Consolidation BFK Shares at exercise prices ranging between $0.67 and $1.04 per share; the holders of the THC Unsecured Debentures will receive replacement unsecured debentures of BFK, the principal amount of which will be convertible into units of BFK at a price of $0.75 per unit, each unit consisting of one post-Consolidation BFK Share and one common share purchase warrant exercisable to acquire one post-Consolidation BFK Share at an exercise price of $0.83 per share; the holders of the THC Secured Debentures will receive replacement secured debentures of BFK, the principal amount of which will be convertible into post-Consolidation BFK Shares at a price of US$0.77 per share; and BFK will change its name to "The Hydropothecary Corporation" or such other similar name as the parties may agree to. It is expected that the share exchange will be structured as a three-cornered amalgamation in which THC will amalgamate with a newly incorporated, wholly-owned subsidiary of BFK to be formed solely for the purpose of facilitating the Transaction. Following the amalgamation, the amalgamated company will be a wholly-owned subsidiary of BFK (renamed as the parties may agree to) and 167151 will be a wholly-owned subsidiary of the amalgamated company. The final legal structure for the Transaction, however, will be determined after the parties have considered all applicable tax, securities law, and accounting efficiencies. As a result of the amalgamation, the current holders of THC Shares (not including future shareholders as a result of the Financing referred to below) will hold approximately 96% of the post-Consolidation BFK Shares and the current holders of the BFK Shares will hold approximately 4% of the post-Consolidation BFK Shares. The Transaction will not constitute a Non-Arm's Length Transaction (as such term is defined in the policies of the Exchange). No Insider, promoter or Control Person (as such terms are defined in the policies of the Exchange) of BFK has any material interest in THC prior to giving effect to the Transaction, except that Greg Misztela, a director of BFK, holds or has a beneficial interest in, directly or through affiliates or associates, 104,810 THC Shares, representing approximately 1.43% of the issued and outstanding THC Shares. These shares were acquired in private placements completed prior to the date of this release. The BFK securities issuable under the Transaction will be subject to the escrow requirements of the Exchange and hold periods as required by applicable securities laws. The Transaction is not subject to approval by the shareholders of BFK. However, at a meeting of the shareholders of BFK to be called in connection with the Transaction, the shareholders of BFK will be asked to approve the Consolidation and, to the extent necessary, approve the appointment of new directors as detailed below. The Transaction is subject to approval by the shareholders of THC, which will be sought at a meeting of the shareholders of THC to be held as soon as practicable. Prior to completion of the Transaction, THC intends to complete a brokered private placement of up to 2,900,000 THC Shares at a price of $4.50 per share for gross proceeds of up to $13.05 million (the "Financing"). THC has engaged Canaccord Genuity Corp. to act as agent in respect of the Financing. Under the Transaction, the THC shareholders resulting from the Financing will receive post-Consolidation BFK Shares in exchange for their THC Shares on the basis of the Exchange Ratio. It is a condition to closing of the Transaction that THC completes the Financing for gross proceeds of at least $10 million. Management and Board of Directors of Resulting Issuer Upon completion of the Transaction, it is expected that the board of directors and management of the resulting issuer will consist of the persons identified below. Mr. St-Louis has been the President and Chief Executive Officer of THC since August 2013. Mr. St-Louis is also the President and founder of Shield Real Estate Investments Inc., founded in 2012. Prior to that, he served as a Senior Account Manager at the Business Development Bank of Canada from 2008 to 2011 and as Chief Financial officer of Wholesale Autoparts Warehouses from 2011 to 2012. Mr. St-Louis holds an MBA, DESS, finance from the Université du Québec à Montréal and a Bachelor of Arts from the University of Ottawa. Prior to Joining THC as Chief Financial Officer in 2014, Mr. Chaplin served as V.P. Finance and Administration for Solacom Technologies Inc. from 2011 to 2014, Interim Corporate Controller at Arise Technologies Inc. in 2011, V.P Finance and Administration at BTI Systems Inc. from 2008 to 2010 and Corporate Controller at Corel Corporation from 2001 to 2008. He obtained his Chartered Professional Accountant, Chartered Accountant designation while working for Ernst and Young from 1996 to 1999. Mr. Chaplin holds a Bachelor of Commerce from Carleton University. Mr. Miron has been the Chief Operating Officer of THC since August 2013. Mr. Miron is the co-founder of iPolitics.ca and was the CIO from 2010 to 2013 and was the National Director of the Federal Liberal Commission from 2007 to 2009 and was responsible for the Federal Liberal Party's online election campaigns. He has experience with online marketing and sales, and brand development. Mr. Miron has also run political campaigns in Canada and abroad. Dr. Munzar is a clinician and is currently serving as Medical Director of Statcare medical clinic in Pointe Claire, Québec. In addition, Dr. Munzar is on the board of directors of Osta Biotechnologies Inc., and has held the position of Vice President of Medical and Regulatory Affairs at Osta since 2005. He served as Medical Director of Nymox Pharmaceutical Corporation from 1996 to 2004 and as the President of Serex Inc., a wholly owned subsidiary of Nymox, from 2000 to 2004. Dr. Munzar has experience in the regulatory development of drugs and medical devices. He obtained his MDCM from McGill University in 1979. Mr. Ewart has been the Chief Executive Officer of GC-Global Capital Corp. since June 2004, as well as Director and Chief Operating Officer since July 2003. Mr. Ewart was a market analyst with A & E Capital Funding Inc. and Bradstone Equity Partners Inc. between 1998 and 2002 and Vice-President of Quest Investment Corporation between 2002 and 2003. He has experience with bridge financing, financial analysis, quantitative modeling, equities trading and mergers and acquisitions. Mr. Ewart holds an economics degree from McGill University. Mr. Chiara is President and sole owner of Group Mach Inc. He began his career in 1984 as a lawyer specializing in real estate transactions and corporate litigation. In 1999, he ceased practicing law and focused on real estate acquisitions and property development through Mach, a private holding company. Mach and its affiliates hold significant investments representing more than 6.5 million square feet of office buildings located in Montreal and throughout Québec. In addition to office and commercial spaces, Mach owns seven million square feet of industrial space, residential and development properties and land for development. Mr. Chiara holds a commerce degree from McGill University and a law degree from the University of Sherbrooke. Mr. Chiara is an independent trustee of Pro Real Estate Investment Trust. It is expected that the directors of the resulting issuer will include two additional individuals to be determined. During the fiscal year ended July 31, 2016, THC had sales of $1,871,781 and a net loss of $3,354,296. As at July 31, 2016, THC had total assets of $9,510,076 and no long term liabilities. The foregoing financial information is unaudited. Financial information for THC will be provided in the filing statement of BFK to be prepared in connection with the Transaction. The completion of the Transaction is subject to the approval of the Exchange and all other necessary regulatory approvals. It is also subject to additional conditions precedent, including: execution of the Definitive Agreement on or before December 9, 2016 or such other date as BFK and THC may agree; satisfactory completion of due diligence reviews by both parties; approvals of the boards of directors of BFK and THC; completion of the Financing by THC for gross proceeds of at least $10 million; preparation and filing of a filing statement outlining the definitive terms of the Transaction in accordance with the policies of the Exchange; receipt of all director, shareholder and requisite regulatory approvals relating to the Transaction, including, without limitation, the approval of the Exchange; any person who will be a post-closing shareholder of BFK which is required by the Exchange to sign an escrow agreement in accordance with the policies of the Exchange shall have signed and delivered such agreement; each of BFK and THC shall have executed, delivered and performed all covenants on its part to be performed under the Definitive Agreement and all representations and warranties of each party contained in the Definitive Agreement shall be true and correct at the time of closing; and at the time of closing the Transaction, THC's license to produce and sell medical marijuana must be in effect and in good standing. The proposed Transaction is subject to the sponsorship requirements of the Exchange. The parties intend to apply for an exemption from the sponsorship requirements of the Exchange. In the event that an exemption is not available, a sponsor will be identified at a later date and will be announced in a subsequent press release of BFK. An agreement to sponsor should not be construed as an assurance with respect to the merits of the transaction or the likelihood of completion of the proposed Transaction. Further details about the Transaction and the resulting issuer will be provided in the filing statement of BFK to be prepared and filed in respect of the Transaction. Investors are cautioned that, except as disclosed in the filing statement, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a Capital Pool Company should be considered highly speculative. Trading in the BFK Shares will be halted as a result of this announcement. Trading in the BFK Shares will remain halted pending the review of the proposed Transaction by the Exchange. There can be no assurance that trading in the BFK Shares will resume prior to the completion of the Transaction. This press release contains forward-looking information based on current expectations. Statements about the closing of the Transaction, expected terms of the Transaction, the number of securities of BFK that may be issued in connection with the Transaction, the ownership ratio of BFK's shareholders post-closing, and the parties' ability to satisfy closing conditions and receive necessary approvals are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Transaction will occur or that, if the Transaction does occur, it will be completed on the terms described above. BFK and THC assume no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Completion of the transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange Requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative. The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, please contact:


News Article | December 22, 2016
Site: www.scientificamerican.com

At the top of the globe in the Canadian Arctic Archipelago, near the North Pole, a thin layer of soil above the permafrost thaws for just three months each year. When it does, the tundra bursts into bloom. The flowers are favorite summer foods of the Peary caribou, Rangifer tarandus pearyi, a petite, white-bearded subspecies of reindeer. With their noses stained red from the flowers of purple saxifrage, they are truly red-nosed reindeer in the summer. But foraging for flowers under summer’s midnight sun is a short-lived luxury. Finding food in winter has always been harder, and climate change is only making the problem worse. Climate is changing twice as quickly in the Arctic compared to the global average. As winters get warmer and wetter, precipitation that falls as rain and then freezes on the ground is increasingly trapping the animals’ food below a crust of ice. Furthermore, declining sea ice is hampering their ability to move from island to island to find enough to eat. Set against a myriad of other ecological challenges, these environmental shifts are putting considerable pressure on the Peary caribou. But the latest scientific findings are informing conservation efforts and provide some reasons to be optimistic about its future. It’s tough to precisely track the number of Peary caribou in Canada’s vast northern reaches. From the piecemeal data that do exist, scientists estimate that 13,200 adult Peary caribou now roam the Arctic Archipelago. That’s more than the 1996 estimate of 5,400 individuals, a low point attributed to winter die-offs from unusually deep snow and food shortages due to ice. But current numbers are still less than the 22,000 estimated in 1987. And although a recent modest rise in numbers prompted the Committee on the Status of Endangered Wildlife in Canada to suggest down-listing the Peary caribou’s status from endangered to threatened in 2015, scientists are concerned that populations might not be able to rebound to historic sizes if the environment changes too much. One particular weather pattern is freezing the Peary caribou’s assets. The reindeer can forage just fine in snow, provided it is not too deep, nosing through the powder to reach the underlying vegetation. But as the Arctic warms, precipitation increasingly takes the form of rain. When rain falls onto snow in the High Arctic winter, it creates a sticky situation that soon freezes solid. The ice that forms on the soggy snow’s surface or in layers below can prevent Peary caribou from accessing the plants they need to survive. Even if the animals survive these difficult freezing events by finding alternate foods, or moving elsewhere, these dips in dietary intake may have consequences in the breeding season. “Females need a certain level of fat in order to reproduce in the spring,“ says Cheryl Johnson of Environment and Climate Change Canada, the country’s environmental science agency. During particularly harsh winters, with deep snow or rain on snow followed by icing, the number of Peary caribou calves observed the following spring can drop to zero. Scientists have long debated the impact of these rain-on-snow and subsequent icing events on Rangifer tarandus—the species called caribou in North America and reindeer in Europe and Asia. In 2010, Nicholas Tyler, a reindeer researcher at the Center for Sami Studies at the University of Tromsø in Norway, published an analysis of all of the available data for rain-on-snow events in North America and Eurasia. He found little evidence for rain on snow being universally dire for caribou and reindeer. It’s an idea that over time, he says, achieved mythical status amongst researchers based on what he calls “enthusiastic interpretation of sometimes meager field data.” He says rain on snow may be important in some populations some of the time, but not in all populations all of the time. Now, though, advances in data analysis from remote sensing are allowing a more rigorous look at how rain on snow and icing affects reindeer. Previously no one had actually examined whether rain-on-snow events had become more frequent in Canada’s High Arctic, Johnson explains. So she and her colleagues at NASA and at Canadian universities in Quebec and Ontario used satellite data to detect and quantify rain-on-snow and icing events across 18 High Arctic islands. They then assessed how well those occurrences aligned with caribou numbers. One of Johnson’s collaborators, remote sensing expert Alexandre Langlois of the University of Sherbrooke, notes that rain-on-snow and icing events can be detected using passive microwave radiography data collected by satellites since 1979 to image the earth. How can satellites detect ground-level phenomena? “Everything that has temperature emits thermal energy,” Langlois explains. The ground emits microwave radiation and snow scatters the signal. “But when you add water from rain, it changes the pattern completely,” he says. Computational algorithms developed by Langlois with University of Sherbrooke colleague Caroline Dolant and others can now detect rain periods, melt periods and ice patterns from the twice-daily satellite passes. Those data provide nearly four decades of coverage for the Canadian Arctic Archipelago, which, although limited for a climate record, is “one of the longest satellite time series that is available,” Langlois says. Examining the microwave data, Johnson and her colleagues found a clear signal that rain-on-snow and icing events have increased in frequency since 1979. Areas with rain-on-snow increases in winter coincided with areas with decreases in caribou numbers the following summer, though it is unclear whether caribou declines reflect mortality or emigration to other areas outside the monitored range. Nevertheless, “if we can understand where these [rain-on-snow and icing] events occur, the frequency of that occurrence, and how spatially that might change through time, then we can assess which areas are at less of a risk,” Johnson says. The next step is to generate maps with finer scale data that can help conservation managers focus their efforts on lower rain on snow and icing areas where Peary caribou are more likely to thrive. Rain on snow and icing are not the Peary caribou’s only challenges, however. Although these reindeer lack flippers and other traits associated with ocean-faring creatures such as whales, Peary caribou are, in fact, marine mammals. For centuries they have trekked from island to island across the sea ice in search of food. Now that sea ice is disappearing. Forming later and thawing earlier each year, the caribou’s inter-island highways are fading away. In addition to keeping the caribou from reaching food sources, the loss of the ice highways could jeopardize the animals in another way. A new study published in 2016 in Biology Letters by Trent University doctoral student Deborah Jenkins and her collaborators analyzed Peary caribou tissue, antler and fecal samples collected across the Canadian Arctic Archipelago. Combining genetic analysis with remote sensing and climate change projections, they found evidence that Peary caribou in the Arctic Archipelago already have less gene flow between populations than continental caribou (a different subspecies) in the lower Arctic mainland. The authors predict that reduced bridging between islands in future will further limit Peary caribou gene flow because isolated populations have fewer opportunities interbreed. But Johnson says that much more work needs to be done to understand where, when and how many Peary caribou cross the sea ice in order to determine what the loss of that ice may mean. And it is not only loss of sea ice itself that may impact Peary caribou crossings: as Arctic waters open up, shipping traffic is increasing, with unknown effects on these animals. Climate change is just one of a multitude of factors affecting Peary caribou numbers. Fluctuations in population sizes of predatory wolves and polar bears, as well as still poorly understood interactions with herbivorous musk oxen that may compete for similar food, could also impact this small reindeer. At this point, no one is certain if the current upswing in Peary caribou numbers is part of the natural cycle of things, Johnson says. In her research, Johnson collaborates closely with Inuit community members and indigenous knowledge has been integrated into every aspect of her research, from helping to develop hypotheses to mapping caribou habitat and identifying where and when they cross the ice. “Without their knowledge we would have very, very little information,” Johnson observes. Indigenous knowledge, she explains, suggests that Peary caribou numbers have always fluctuated wildly through time. The current low numbers may thus be part of a very long-term natural cycle that will eventually usher in larger numbers. Caribou researcher Micheline Manseau of the government agency Parks Canada, shares Johnson’s cautious optimism about the fate of the Peary caribou. Even with the predicted eventual loss of most sea ice, it’s not the first time in their evolutionary history that these caribou have had to change their movement patterns. There is evidence that some of Peary populations have gone through genetic bottlenecks in the past. Manseau suspects the creature will be able to thrive on the larger islands, which can be more than twice the size of Maine. Other evidence supports this hopeful outlook for Canada’s diminutive, red-nosed reindeer, too. Carbon dating of ancient poop suggests that Norway’s Svalbard reindeer, which are similar in many ways to their Peary cousins, arrived on their now isolated Arctic archipelago 5,000 years ago. Crossing the sea ice from Eurasia, and becoming stranded there some time later, the Svalbard reindeer are “living proof,” Tyler says, “that these island populations can exist for a long time.”


News Article | April 14, 2016
Site: www.biosciencetechnology.com

Catherine Aaron and Gabrielle Beaudry were 17 when they knocked on the door of the laboratory of Alex Parker, a neuroscience researcher at the University of Montreal Hospital Research Centre (CRCHUM). While students at Collège Jean-de-Brébeuf in Montreal, they were looking for a mentor for an after-school research project. Two and half years later, the results of this scientific adventure were published today in the Journal of Agricultural and Food Chemistry. "We wanted to test the effect of a natural product on a neurodegenerative disease such as Alzheimer's. Professor Parker had already discovered that sugar prevents the occurrence of amyotrophic lateral sclerosis (ALS) in an animal model of the disease, the C. elegans worm. That's how we got the idea of maple syrup, a natural sugar produced in Quebec," said Beaudry. Supervised by Ph.D. student Martine Therrien and Alex Parker, Aaron and Beaudry added maple syrup to the diet of these barely 1 mm-long nematodes. "We just gave them a supplement of maple syrup at various concentrations and compared with a control group that had a normal diet," said Aaron. "After twelve days, we counted under the microscope the worms that were moving and those that were paralyzed. The worms that had consumed the highest dose of syrup were much less likely to be paralyzed." Alex Parker's C. elegans worms are genetically modified to express a protein involved in ALS in motor neurons - TDP-43. "When they are adults, around 12 days, their motor neurons break down. Normally, at two weeks of life, 50 percent of the worms are completely paralyzed. But among those that received a diet enriched with 4 percent maple syrup, only 17 percent were paralyzed. We can therefore conclude that maple syrup protects neurons and prevents the development of amyotrophic lateral sclerosis in C. elegans worms," said Parker, a researcher at the CRCHUM and professor at the Faculty of Medicine, University of Montreal. How can we explain this dramatic effect? "Sugar is good for the nervous system. Diseased neurons require more energy to combat toxic proteins. But maple syrup is rich in polyphenols, powerful antioxidants found in certain foods. We isolated phenols contained in the maple syrup, and we showed that two polyphenols in particular, gallic acid and catechol, have a neuroprotective effect. In pure maple syrup, these polyphenols are found in low concentrations. Probably a combination of sugar and polyphenols prevents the occurrence of the disease in worms," said Therrien, a Ph.D. student at the CRCHUM. But don't go ahead and gorge yourself on maple syrup thinking it'll protect you against neurological diseases! "The life expectancy of C. elegans worms is only three weeks. They are spared the long-term toxic effects of sugar. Humans who consume comparable amounts of sugar risk developing chronic diseases such Type 2 diabetes and obesity," cautioned Parker. Amyotrophic lateral sclerosis is a rare neuromuscular disease that causes paralysis and death a few years after the onset of symptoms. So far, no cure is available for patients. This latest study on maple syrup and the C. elegans worm was conducted for educational purposes. Other studies by Alex Parker with C. elegans have led to the discovery of promising drugs, which will be tested in patients in a few years. Catherine Aaron and Gabrielle Beaudry won the Sanofi Biogenius Canada People's Choice Award - Quebec section - for this project in April 2014. Aaron is now a first-year medical student at the University of Montreal, and Beaudry studies psychology at the University of Sherbrooke.


GATINEAU, QUEBEC--(Marketwired - Nov. 1, 2016) - Nouveau Monde Mining Enterprises Inc. (TSX VENTURE:NOU)(OTC PINK:NMGRF)(FRANKFURT:NM9) ("Nouveau Monde") is pleased to announce that it has appointed Charles-Olivier Tarte as Chief Financial Officer effective November 1, 2016. Mr. Tarte will replace Martin Nicoletti, who remains with the company as Corporate Controller. Mr. Tarte will be based in the Company's offices in Montreal. Mr. Tarte is a Chartered Professional Accountant, Certified Management Accountant and has more than 5 years of experience in the graphite industry. Recently, Mr. Tarte has been the Natural Graphite Financial Controller for Imerys Graphite & Carbon. As such, he has overseen the financial management of the Lac-des-Îles (QC) natural graphite mine, the Terrebonne (QC) second transformation plant & the Westlake (OH) Americas sales office. Mr. Tarte is a graduate of the University of Sherbrooke where he obtained his Bachelor of Commerce in Accounting and Finance. Mr. Tarte tasks will focus on strategic planning and the financial optimization of our operations. Eric Desaulniers, President & CEO of Nouveau Monde, stated: "Charles-Olivier's recent operational experience in the natural graphite industry along with his personal skillset will definitely strengthen our management team and is in line with our desire to build a first-class group of individuals to develop our Matawinie graphite project." Nouveau Monde granted 250,000 options to Charles-Olivier Tarte as part of his employment package. Each option shall entitle to subscribe for one common share of the Corporation, at a price of $0.25 per common share, for a period of five years from the date of grant. These options will vest one quarter at issuance and by period of three months until August 1st, 2017. These options were granted in accordance with the terms of the current stock option plan of the Corporation. Nouveau Monde owns the Matawinie's Tony graphite deposit discovered by the company in 2015 on which a 43-101 Preliminary Economical Assessment was completed in June 2016 which demonstrated strong economics for the production of 50,000 tpy of high purity flake graphite for 25.7 years with solid a operational margin and relatively low capital expenditure (http://nouveaumonde.ca/matawinie-summary/). The project is located in the Saint-Michel-des-Saints area, some 130 km north of Montreal, Quebec, Canada with direct access to all needed infrastructure, labor and green and affordable hydroelectricity. Nouveau Monde is developing its project with the highest corporate social responsibility standards and the lowest environmental footprint (targeting a net zero carbon emission operation). Eric Desaulniers, M.Sc., P.Geo., a Qualified Person under NI 43-101 guidelines, has reviewed and is responsible for Nouveau Monde's technical information presented in this news release. Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) has in any way passed upon the merits of the proposed transaction or approved or disapproved the contents of this press release. Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those anticipated by such statements. Nouveau Monde will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Nouveau Monde.


Melancon M.O.,Université de Sherbrooke | Melancon M.O.,University of Sherbrooke
Applied Physiology, Nutrition and Metabolism | Year: 2015

Normal aging entails significant changes in serotonergic activity and function. Noteworthy, these alterations might predispose older individuals to develop depressive symptoms and contribute to age-related changes in sleep. This study verified if exercise increases tryptophan (Trp) availability to the brain and affects sleep depth and architecture in older men. Nineteen men (aged 64 ± 3 years) undertook a series of 4 tests, which was repeated at follow-up (after 16 weeks of training) as follows: (i) dual-energy X-ray absorptiometry (body composition); (ii) peak O2 consumption, ventilatory threshold, and respiratory compensation point (cardiopulmonary testing); (iii) blood withdrawals immediately before, during, and after exercise for analysis of glucose, lactate, ammonia, free fatty acids (FFA), total proteins, albumin, prolactin, valine, leucine, isoleucine, adiponectin, leptin, free and total Trp, and calculated variable: branched-chain amino acids (BCAA); and (iv) sleep electrophysiology (wake, stage 1, stage 2, stages 3+4 or slow-wave sleep (SWS), stage 5 or rapid eye movements, movement time, leg movements during sleep, apneas, hypopneas, and derivative variables). The intervention consisted of supervised exercise (3× per week × 45 min, 65%–70% peak oxygen uptake (VO2peak) whereas experimental exercise consisted of 1 h of inclined treadmill (~68% VO2peak). Variations in serum prolactin and free Trp/BCAA served as proxies of 5-hydroxytryptamine activity and synthesis rate, respectively. A series of 3 nights was assessed before and after training using laboratory-based sleep electrophysiology (polysomnography: electroelectroencephalography and electromyography and electro-oculography) as follows: (i) familiarization, (ii) inactive trial, and (iii) exercise trial. Aerobic taining increased oxygen uptake at both ventilatory thresholds, whereas body mass decreased. Acute exercise increased free Trp/BCAA ratio by more than 100% of that at rest and remained elevated postexercise. This ratio shared a positive association with FFA levels. After 1 h of exercise, prolactin was higher than that at rest and was positively associated with free Trp/BCAA. However, the acute response to exercise was attenuated following training for many compounds, including free Trp/BCAA, prolactin, lactate, and FFA. Analyses revealed significant main effects of exercise on wake after sleep onset, rapid eye movement onset latency, and time awake overnight. As compared with the inactive trial at baseline, a higher proportion of SWS was observed during the night subsequent to exercise following training. In addition, we found a positive association between resting adiponectin and SWS. The results support the hypothesis that increases in serotonin synthesis and activity might be involved in the antidepressant outcome of exercise in older men. Inasmuch as training lowered the increase in Trp supply during exercise, Trp requirement by the brain in response to exercise might be attenuated by training. Despite gains in cardiorespiratory fitness after training, a day without exercise led to SWS values similar to those at baseline. However, exercise increased the proportion of SWS during subsequent sleep but this could only be found after training. These results provide evidence that not only sleep quantity (duration) but also quality (SWS) could affect circulating adiponectin levels. Finally, a positive correlation was found between sleep depth and circulating adiponectin levels. ©, 2006 National Research Council of Canada. All rights reserved.


Ammari M.L.,Laval University | Roy S.,University of Sherbrooke
2016 International Conference on Computing, Networking and Communications, ICNC 2016 | Year: 2016

This paper provides a performance analysis of communication systems over Rayleigh-product single-output multiple-output (SIMO) channels with maximal-ratio combining (MRC) and selection combining (SC). New closed-form expressions for the exact cumulative distribution function (CDF) and probability density function (PDF) of the post-combining signal-to-noise ratio (SNR) are derived. Then, the performance of MRC and SC techniques, in terms of outage probability and average symbol error rate (SER) is derived. Furthermore, we present new expressions for key metrics characterizing the system performance at the high and low signal-to-noise ratio (SNR) regimes. Monte-Carlo simulation results are presented and their results concur with the analytical results. © 2016 IEEE.


Nakanishi M.,Tokyo Metropolitan Institute of Medical Science | Miyamoto Y.,University of Tokyo | Long C.O.,Capstone Healthcare and Palliative Care Essentials | Arcand M.,University of Sherbrooke
International Journal of Palliative Nursing | Year: 2015

Background: A Canadian guide for nursing home staff on comfort care for dementia has been translated and adapted for use in Japan. The present study piloted educational intervention for nursing home staff using the Japanese comfort care booklet. Method: Some 61 nursing home staff (nurses and other care workers) completed a session that included pre-assessment, a 30-minute seminar using the comfort care booklet, post-assessment, and a one-hour debriefing meeting. A Japanese version of the questionnaire on palliative care for advanced dementia (qPAD) scale was used to assess knowledge and attitudes toward palliative care for advanced dementia. Results: The participants demonstrated a significant increase in knowledge (mean score, 14.3 to 15.1/23, t (60) = 2.35, p=0.011) and attitudes (43.8 to 45.2/60, t (60) = 2.51, p=0.015) toward palliative care for advanced dementia from pre-assessment to post-assessment. Conclusion: The educational intervention using the Japanese comfort care booklet may have improved nursing home staff's perspectives on palliative care for advanced dementia. © 2015 MA Healthcare Ltd.


News Article | September 7, 2016
Site: www.nature.com

As the climate warms, sugar maples expanding their populations uphill could outrun their insect predators and flourish on the 'happy edge' of their range. Morgane Urli and her colleagues at the University of Sherbrooke in Quebec, Canada, transplanted two-year-old sugar maples (Acer saccharum) uphill to sites just at, and beyond, their current elevation range limit. Some were given protection from herbivores. Of seedlings without protection, more than 75% at the range edge and beyond survived, compared with just 30% at the centre of the current range. The difference narrowed markedly in protected plants, suggesting that the increased survival was largely due to 'enemy release' at and beyond the current range. Previously, the team showed that seed predation beyond elevation range limits is very high. However, those few seeds that do escape can look forward to a healthy future.


"We have been wondering what influence selective hunting has on the evolution of a species," says David Coltman, professor of biological sciences at the University of Alberta. "What you have here is clearly artificial selection. You can imagine that harvested animals don't have any more offspring. Their genes are removed from the gene pool." Coltman recalls Darwin's observation that the system of killing only the finest stags on Scottish estates may cause red deer to degenerate. Ironically, hunting based on minimum size criteria—such as horn size—selects against the trait most desired by hunters: the size of the trophy. "Conventional wisdom is that the bigger your horns are, the better you do because you're better armed than the competition," says Coltman. "This is partially true, but it's quite age-dependent. It's not just the size of your horns, but also how old you are. For a ram to become highly successful and socially dominant, he's not just large-horned. He's also experienced." Rams are often shot prior to reaching that age of experience. "It doesn't take a big stretch as an evolutionary biologist to recognize that this is strong selection pressure." Dominant rams reach their peak reproductive years at age eight to 10, long after their horns reach the legal age for trophy hunting, which in Alberta is currently a four-fifths curl, when the tip of the horn is parallel with the eye. Coltman and his colleagues on the study—Gabriel Pigeon, Marco Festa-Bianchet, and Fanie Pelletier from the University of Sherbrooke—concentrated on data collected from bighorn sheep on Ram Mountain near Nordegg, Alberta. Their analysis of 39 years' worth of data collected on the sheep that were subject to intense trophy hunting for 23 of those years supports the contention that selective hunting led to a reduction in horn length through evolutionary change. "For 30 years in Alberta, the number of trophy rams has been declining, and the age of these legal rams is increasing. This signals that what we are seeing at Ram Mountain may be true across wider areas." Coltman says there are many more licences issued to trophy hunters than there are available legal rams. "What we see is a decline in horn size over time," he says, noting the average size of a set of horns at Ram Mountain has declined more than 20 per cent over 43 years. Another startling result from the study is that after artificial selection stops, recovery of horn length through natural selection is slow. "You can't imagine a stronger selection pressure than hunting based on a measurable morphometric trait," Coltman emphasizes. "What we have here is a very hard-edged selection. We simply need to reduce the selective edge by taking fewer rams or re-examining size requirements. If we stop hunting based on horn size, the horn size will increase, albeit slowly. We have to be more evolutionarily enlightened about how we manage and conserve animal populations." Coltman's research focuses on the maintenance and adaptive significance of genetic variation in the wild. He also tests evolutionary theory in natural populations using longitudinal data and pedigrees and applies genetic methods to problems in conversation and wildlife management. He has been involved with the pedigree work and genetics of the Ram Mountain bighorn sheep population since 1999. The findings, "Intense selective hunting leads to artificial evolution in horn size," will be published in the journal Evolutionary Applications. Explore further: Personality types may contribute to genetic success of bighorn sheep

Loading University of Sherbrooke collaborators
Loading University of Sherbrooke collaborators